Literature DB >> 10519398

Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility.

C S Huang1, H D Chern, K J Chang, C W Cheng, S M Hsu, C Y Shen.   

Abstract

Estrogen has been proposed to trigger breast cancer development via an initiating mechanism involving its metabolite, catechol estrogen (CE). To examine this hypothesis, we conducted a multigenic case-control study to determine whether polymorphisms of the genes responsible for CE formation via estrogen biosynthesis (CYP17) and hydroxylation (CYP1A1) and CE inactivation (COMT) are associated with an elevated risk for breast cancer in Taiwanese women, and whether the association between genotype and risk may be modified by estrogen exposure. One hundred and fifty breast cancer patients and 150 healthy controls were recruited. PCR-based RFLP assays were used to determine the genotypes of estrogen-metabolizing genes. The breast cancer risk associated with individual susceptibility genotypes varied among the three genes and was highest for COMT, followed by CYP1A1 and CYP17. After simultaneous consideration of all three genes and other well-established risk factors of breast cancer, the COMT genotype remained the most significant determinant for breast cancer development and was associated with a 4-fold increase in risk (95% confidence interval, 1.12-19.08). Furthermore, a trend of increasing risk for developing breast cancer was found in women harboring higher numbers of high-risk genotypes (P = 0.006), including the high activity CYP17 (CYP17 A2/A2), high inducibility CYP1A1 (CYP1A1 MspI vt/vt), and low activity COMT (COMT L/L) genotypes. The association of risk with the number of susceptibility genotypes was stronger in women with prolonged estrogen exposure (indicated by a higher number of estrogen exposure years or a higher number of estrogen exposure years between menarche and first full-term pregnancy), women with higher estrogen levels (implied by early menarche), and women with a higher body mass index (> or = 22.5). On the basis of comprehensive profiles of estrogen metabolism, this study supports the possibility that breast cancer can be initiated by estrogen exposure.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10519398

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  56 in total

Review 1.  Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility.

Authors:  M M de Jong; I M Nolte; G J te Meerman; W T A van der Graaf; J C Oosterwijk; J H Kleibeuker; M Schaapveld; E G E de Vries
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

2.  Oligogenic combinations associated with breast cancer risk in women under 53 years of age.

Authors:  Christopher E Aston; David A Ralph; Dominique P Lalo; Sharmila Manjeshwar; Bobby A Gramling; Daniele C DeFreese; Amy D West; Dannielle E Branam; Linda F Thompson; Melissa A Craft; Debra S Mitchell; Craig D Shimasaki; John J Mulvihill; Eldon R Jupe
Journal:  Hum Genet       Date:  2004-12-21       Impact factor: 4.132

3.  High-resolution chromosome 3p allelotyping of breast carcinomas and precursor lesions demonstrates frequent loss of heterozygosity and a discontinuous pattern of allele loss.

Authors:  A Maitra; I I Wistuba; C Washington; A K Virmani; R Ashfaq; S Milchgrub; A F Gazdar; J D Minna
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

Review 4.  Pharmacogenomics: catechol O-methyltransferase to thiopurine S-methyltransferase.

Authors:  Richard M Weinshilboum
Journal:  Cell Mol Neurobiol       Date:  2006-06-29       Impact factor: 5.046

5.  Identification of a novel haplotype of the human catechol-O-methyltransferase gene.

Authors:  Hyoung-Woo Bai; Bao Ting Zhu
Journal:  Pharmacogenet Genomics       Date:  2009-01       Impact factor: 2.089

6.  Catechol-O-methyltransferase: effects of the val108met polymorphism on protein turnover in human cells.

Authors:  Anne E Doyle; James D Yager
Journal:  Biochim Biophys Acta       Date:  2007-10-16

7.  A prospective study of genetic polymorphism in MPO, antioxidant status, and breast cancer risk.

Authors:  Chunyan He; Rulla M Tamimi; Susan E Hankinson; David J Hunter; Jiali Han
Journal:  Breast Cancer Res Treat       Date:  2008-03-14       Impact factor: 4.872

Review 8.  Estrogen receptor alpha in human breast cancer: occurrence and significance.

Authors:  S Ali; R C Coombes
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-07       Impact factor: 2.673

9.  Epistatic and functional interactions of catechol-o-methyltransferase (COMT) and AKT1 on neuregulin1-ErbB signaling in cell models.

Authors:  Yoshitatsu Sei; Zhen Li; Jian Song; Renee Ren-Patterson; Elizabeth M Tunbridge; Yukihiko Iizuka; Masahiro Inoue; Berenice T Alfonso; Senda Beltaifa; Yoko Nakai; Bhaskar S Kolachana; Jingshan Chen; Daniel R Weinberger
Journal:  PLoS One       Date:  2010-05-24       Impact factor: 3.240

10.  Multi-variant pathway association analysis reveals the importance of genetic determinants of estrogen metabolism in breast and endometrial cancer susceptibility.

Authors:  Yen Ling Low; Yuqing Li; Keith Humphreys; Anbupalam Thalamuthu; Yi Li; Hatef Darabi; Sara Wedrén; Carine Bonnard; Kamila Czene; Mark M Iles; Tuomas Heikkinen; Kristiina Aittomäki; Carl Blomqvist; Heli Nevanlinna; Per Hall; Edison T Liu; Jianjun Liu
Journal:  PLoS Genet       Date:  2010-07-01       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.